Clinical Trials Logo

Neuromuscular Blockade clinical trials

View clinical trials related to Neuromuscular Blockade.

Filter by:

NCT ID: NCT03660891 Not yet recruiting - Clinical trials for Neuromuscular Blockade

OS NMB Depth Measured by Central and Peripheral Monitor.

Start date: August 1, 2020
Phase:
Study type: Observational

Comparing during anesthesia in the same patient 2 neuromuscular monitors on the same arm.

NCT ID: NCT03656614 Completed - Clinical trials for Neuromuscular Blockade

Reversal of Residual Neuromuscular Blockade at Train-of-four Ratio 0.3 With Sugammadex and Neostigmine

Start date: July 26, 2018
Phase:
Study type: Observational [Patient Registry]

The aim of this study is to estimate the optimal dose of sugammadex and neostigmine reversal of a vecuronium-induced residual neuromuscular block at train-of-four ratio 0.3.

NCT ID: NCT03649672 Terminated - Clinical trials for Neuromuscular Blockade

The Validity and Tolerability of Awake Calibration of the TOF Watch SX Monitor

CaliRev
Start date: October 26, 2018
Phase: N/A
Study type: Interventional

Neuromuscular blocking agents (NMBAs) are frequently used in anesthesia and quantitative monitoring of neuromuscular block is standard care. Normally the calibration of the neuromuscular monitor is done after anesthesia induction to avoid patient discomfort. Under certain circumstances there is no time for the calibration process. In the so-called rapid sequence induction (RSI) the neuromuscular blocking agent has to be injected immediately after the induction agent. As the neuromuscular monitor cannot be calibrated, precise neuromuscular monitoring is not possible, and this is of particular disadvantage, when high doses of non-depolarizing neuromuscular blockers are injected to fasten the onset of neuromuscular block. The primary objective is to validate the measurements of the TOF Watch SX® monitor calibrated in awake patients by comparing them with the measurements obtained with the TOF Watch SX® monitor calibrated after anesthesia induction (Gold standard). The secondary objective is to evaluate the tolerability of the awake calibration process of the TOF Watch SX® monitor.

NCT ID: NCT03608436 Completed - Surgery Clinical Trials

The Effect of Low Pressure Pneumoperitoneum During Laparoscopic Colorectal Surgery on Early Quality of Recovery

RECOVER
Start date: October 24, 2018
Phase: Phase 4
Study type: Interventional

Randomised controlled trial comparing the effect of low pressure pneumoperitoneum with deep neuromuscular block versus normal pressure pneumoperitoneum with moderate neuromuscular block during laparoscopic colorectal surgery on early quality of recovery.

NCT ID: NCT03605628 Completed - Clinical trials for Neuromuscular Blockade

Influence of Analgesia and Neuromuscular Block on Abdominal Distension and Operating Conditions Laparoscopic Operations

Start date: July 1, 2018
Phase: N/A
Study type: Interventional

Neuromuscular block improves operation conditions during laparoscopic surgery. In this study, a new measurement tool is assessed: the degree of abdominal distension during the time course of the neuromuscular block is measured and compared with a standardized score (surgical rating score).

NCT ID: NCT03605225 Recruiting - Clinical trials for Neuromuscular Blockade

Development and Validation of an Android-based Application for Anaesthesia Neuromuscular Monitoring

Start date: February 7, 2018
Phase: N/A
Study type: Interventional

The present study aims to assess the accuracy of a newly developed Android Smartphone Application in measuring the degree of Neuromuscular block in the perioperative period. This will be achieved by comparing Train-of-four Ratio measurements using this application with those obtained from a standard commercialized neuromuscular monitor.

NCT ID: NCT03588689 Completed - Pain Clinical Trials

Continuous Fascia Iliaca Block for Acute Hip Fractures

Start date: May 7, 2018
Phase: Phase 4
Study type: Interventional

Hip fractures are a major cause of morbidity and mortality in the elderly with over 30,000 hip fractures occuring in Canada annually and over 1300 in Saskatchewan. The estimated cost associated with hip fractures is over $600 million nationally and 28 million dollars in Saskatchewan. Hip fractures cause a great deal of pain and immobility and are mainly treated with surgical fixation. In the perioperative period, hip fracture patients are treated mainly with opioids and other adjuncts such as NSAIDS and acetaminophen. Opioid consumption in the elderly population can predispose to delirium and respiratory complications such as atelectasis, respiratory depression, and pneumonia. Fascia iliaca blocks have been shown to be an effective mode of analgesia for patients with hip fractures, but are underutilized for varying reasons including culture of practice, expertise with performing the block, and having a dedicated service to do so. This study aims to compare the efficacy of fascia iliaca blocks to standard treatment (opioids) in the management of pain in hip fracture patients with a particular focus on outcomes such as the incidence of delirium, respiratory complications, and length of stay in hospital. Our idea is that if we can reduce the amount of opioids these patients receive then they will have improved pain control, fewer respiratory complications, earlier time to mobilizing, and shorter hospital stays. As far as we are aware this relation has not been well studied.

NCT ID: NCT03585348 Completed - Clinical trials for Neuromuscular Blockade

Provider Variability in the Use of Neuromuscular Blocking Drugs and Reversal

Start date: June 29, 2018
Phase:
Study type: Observational

The use of neuromuscular blocking agents during surgery is associated with postoperative respiratory complications and increased risk of readmission to the hospital following ambulatory surgery. Understanding the clinical behavior of providers is essential in devising and assessing quality improvement projects since it is primarily individuals who determine the utilization of neuromuscular blocking drugs and reversal agents, not institutions. Therefore, the primary objective of this study is to determine the variability between individual anesthesia providers (attending physician, resident, nurse anesthetists) in the use of neuromuscular blocking drugs and reversal agents, using advanced statistical methods to adjust for differences in patient and procedure case mix. The investigators hypothesize that variance between individual anesthesia providers in the use of neuromuscular blocking drugs and reversal agents differs depending on provider type.

NCT ID: NCT03579589 Completed - Clinical trials for Neuromuscular Blockade

The Effect of Sugammadex Versus Neostigmine During Neuromuscular Blockade Reversal

Start date: August 15, 2018
Phase: Phase 1
Study type: Interventional

Patients who undergo surgery receive drugs called neuromuscular blocking agents (NMBA) that to block the activity of muscles. When the surgery is over, the block needs to be reversed. Suggammadex and neostigmine are examples of drugs that reverse blocks. This study aims to investigate if sugammadex is associated with a significantly reduced time to discharge from the operating room to the postoperative unit when compared to neostigmine.

NCT ID: NCT03572413 Completed - Surgery Clinical Trials

The Effect of Low Pressure Pneumoperitoneum During Laparoscopic Colorectal Surgery on Innate Immune Homeostasis.

RECOVER-PLUS
Start date: October 24, 2018
Phase: Phase 4
Study type: Interventional

Substudy of the RECOVER trial (a randomised controlled trial comparing the effect of low pressure pneumoperitoneum with deep neuromuscular block versus normal pressure pneumoperitoneum with moderate neuromuscular block during laparoscopic colorectal surgery on early quality of recovery) investigating innate immune homeostasis after laparoscopic colorectal surgery.